A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology - Trial NCT06043700
Access comprehensive clinical trial information for NCT06043700 through Pure Global AI's free database. This phase not specified trial is sponsored by Eisai Limited and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eisai Limited
Eisai Inc.
Timeline & Enrollment
N/A
Sep 12, 2023
Mar 31, 2025
Primary Outcome
Number of Participants With Low, Medium, and High Amyloid Pathology
Summary
The primary purpose of this study is to identify participants with or without symptoms of
 Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based
 biomarkers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06043700
Non-Device Trial